Suggested remit: To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for maintenance treatment of extensive-stage small-cell lung cancer after chemotherapy.
Following on from information provided to NICE by the company in September 2019, the appraisal of Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1264
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 November 2022 | Discontinued. Following on from information provided to NICE by the company in September 2019, the appraisal of Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 September 2019 | Suspended. Referred 22/07/2016 |
| 16 September 2019 | Note added to the project documents |
| 17 October 2018 - 14 November 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 22 July 2016 | Referral |
| 22 July 2016 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual